Er du tungt inne enda? Kastet kortene nylig selv.
Har ikke gjort noe her, men er heller ikke investert på grunn av Kaydence, det er bare krydder. Håper de blir bedre på kommunikasjon med markedet fremover.
1 Like
I dag kl 02:5853
03 October 2019
Dear Kaydence Pharma shareholders:
While we are encouraged with the feedback we have received in many of these meetings, we must also emphasize that we are still in pursuit of a lead investor to enable the company to begin the next stage of our program. Our ability to secure this necessary funding currently represents a near-term risk to the overall development plan and the company’s operations going forward. In recognition of these challenges, we have already taken, and continue to implement, extraordinary measures to ensure that we have the maximum possible runway in order to maintain our efforts in the months ahead. We are also pleased to share that as part of these measures NattoPharma ASA has issued a waiver to Kaydence AS related to the debt financing and repayment schedule. This agreement will
Our efforts to identify potential partners have included both early stage venture capital groups and industry strategic players. Overall, I believe that the potential therapeutic benefits of our program and validity of our investment case have been well-received. At one of the major events of the summer, the
Start- up Stadium, a forum designed to highlight emerging biotech companies. This was a juried competition in
which we presented our company and investment case to a panel of ten judges, whose expertise included venture investing, research and biotechnology. We were one of five overall winners, from an original field of over 150 applicants across 13 countries. The competition is intended to provide early stage innovative companies in the medical/therapeutic space a forum in which to gain exposure and recognition. For Kaydence, this result was a positive validation of our development objectives and investment case.
During the broader BIO-International Convention, which is one of the largest annual forums for the pharmaceutical and biotech industries, we held over 40 one-on-one meetings with potential investors and commercial partners. We continue to be actively engaged in discussions emanating from this event. In addition to the BIO-International Convention, we have also been active in the US-based Kidney Health Initiative and the more recently held LSX Nordic Congress for biotech companies.
At a broader health policy level there was a significant development this summer that we believe will focus needed attention on the renal disease space. In July the US administration made a major announcement which directed the US Department of Health and Human Services to develop policies addressing three goals: reducing the number of patients developing kidney failure, reducing the number of patients receiving dialysis treatment at dialysis centers and making more kidneys available for transplant. We believe our development program at Kaydence has a compelling fit with the first of these three goals: our program holds the promise of reducing both the severity and occurrence of renal impairment leading to end stage renal disease. We are also hopeful that this level of attention, driven by the enormous health and cost burden imposed by kidney disease, will be a catalyst for innovative therapies in a space that is in need of new treatment strategies.
In our April update we highlighted ongoing fund-raising activities including several partnering and
industry events which were scheduled during the summer months. We have been diligently engaging in
these meetings and our top priority continues to be on securing funds for the next phase of our
development plan.
provide increased flexibility for Kaydence and allow us to continue to focus resources on the next round
of funding.
2019 BIO-International Convention, we received outstanding recognition as part of the competitive
Kaydence Pharma AS
Norway: Lileakerveien 2B, N-0263 Oslo
USA: 50 Herbert Drive, East Brunswick, NJ 08816
info@kaydencepharma.com www.kaydencepharma.com
On the academic front we continue to see increasing interest in the impact of vascular calcification on
disease burden. Matrix Gla Protein, one of the critical elements of our program, seems to be gaining
by Dr. Julio Chirinos, a research cardiologist at Perelman School of Medicine, University of Pennsylvania, and one of our medical
advisors. The paper was featured in the Journal of the American College of Cardiology in its State-of- the-Art Review section. The review focused on the importance of large artery stiffness as an independent predictor of cardiovascular risk, and specifically identified this issue as a high priority target in managing renal disease. The paper directly addressed the detrimental impact that arterial stiffening has on kidney function and further highlighted Matrix Gla Protein as a “particularly attractive and clinically relevant therapeutic target.” Further, the paper was chosen as the CME/MOC paper of the month
particular attention. An example is a paper published earlier this month
The continuing academic attention, investigator-led trials and broader interest in finding innovative
treatments to address renal disease are all encouraging initiatives that help support the case for our
development program. The next phase of our program will require new funding, and thus our number one
priority must be, and is, to secure a lead investor or strategic sponsor. These efforts will continue to be
our primary focus over the coming months.
Kaydence Pharma AS
Norway: Lileakerveien 2B, N-0263 Oslo
USA: 50 Herbert Drive, East Brunswick, NJ 08816
info@kaydencepharma.com www.kaydencepharma.com
1 Like
medling / flaggning
Meldepliktig handel
Det blir tungt i NATTO hvis de skal drive å selge slike småposter framover 
2 Likes
Sjur sitter forløpig på hendene og lar LSS dumpe ut en illikvid aksje
1 Like
Det store spørsmålet er jo hvor mye de har tenkt å selge men ser ut som det kan bli en god kjøpsmulighet for de som har troen på selskapet. Vil uansett ikke kalle det de holder på med for å dumpe 
1 Like
Meldepliktig handel
Egentlig ganske utrolig at de gjør det på denne måten og ser virkelig fram til å få slike børsmeldinger de neste 250 dagene
2 Likes
NattoPharma ASA: Invitation to presentation of third quarter 2019 financial results
1 Like
Medling Natto
1 Like
Medling
“Medling”?
2 Likes
Trodde jo først det var melding på svensk men det var det ikke 
Vitamin K2 as MK-7 shown to improve endothelial function
medling
1 Like
Record quarter and strong pipeline
Fin rapport igjen, “back on track”? 2.9 mnok pluss i et sesongmessig dårlig kvartal.
Det negative er vel utviklingen i Kaydence som dessverre sliter med å hente kapital. Men dagens mcap er absolutt ikke avhengig av noe støtte fra Kaydence slik jeg ser det.
3 Likes